Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.57 |
| ▸ | ADRB2 | P07550 | 17/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 15/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.44 |
| ▸ | MLNR | O43193 | 1/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | MC3R | P41968 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.44 |
| ▸ | GHSR | Q92847 | 1/20 | 0.44 |
| ▸ | ADRB3 | P13945 | 14/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10416913 | 1.00 | SLC2A1 (0.57) | SLC2A1ADRB2ADRB1SLC6A2HTR2A | |
| Picumeterol SCHEMBL83175 | 1.00 | SLC2A1 (0.57) | SLC2A1ADRB2ADRB1SLC6A2HTR2A | |
| Picumeterol SCHEMBL156907 | 1.00 | SLC2A1 (0.57) | SLC2A1ADRB2ADRB1SLC6A2HTR2A | |
| Picumeterol SCHEMBL9857897 | 1.00 | SLC2A1 (0.57) | SLC2A1ADRB2ADRB1SLC6A2HTR2A | |
| SCHEMBL10391329 | 0.99 | SLC2A1 (0.57) | SLC2A1ADRB2ADRB1SLC6A2HTR2A | |
| SCHEMBL10418436 | 0.96 | SLC2A1 (0.59) | SLC2A1ADRB2ADRB1SLC6A2HTR2A | |
| SCHEMBL10416519 | 0.96 | SLC2A1 (0.59) | SLC2A1ADRB2ADRB1SLC6A2HTR2A | |
| SCHEMBL9741835 | 0.96 | SLC2A1 (0.57) | SLC2A1ADRB2ADRB1SLC6A2HTR2A | |
| Picumeterol SCHEMBL9858096 | 0.93 | SLC2A1 (0.68) | SLC2A1ADRB2ADRB1SLC6A2HTR2A | |
| Picumeterol SCHEMBL9325626 | 0.93 | SLC2A1 (0.54) | SLC2A1ADRB2ADRB1SLC6A2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119684295-A | Bicyclic compounds for treating diseases and uses thereof | 雅斯娜制药公司 | 2025-03-25 | — | — | CN | disclosed |
| EP-4518866-A1 | METHODS OF TREATING FIBROSIS | Athira Pharma, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| EP-4518864-A1 | METHODS OF TREATING NEUROPATHIES | Athira Pharma, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| CN-119300834-A | Methods of treating neuropathy | 雅斯娜制药公司 | 2025-01-10 | — | — | CN | disclosed |
| EP-4448100-A1 | USES OF BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASES | Athira Pharma, Inc. (US) | 2024-10-23 | — | — | EP | disclosed |
| EP-4313955-A1 | PYRIMIDINE DERIVATIVES USEFUL AS LRRK2 KINASE INHIBITORS | Halia Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| WO-2024006994-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER BY TARGETING THE BRCA1 PSEUDOGENE 1 (BRCA1P1) | THE UNIVERSITY OF CHICAGO (US) | 2024-01-04 | — | — | WO | disclosed |
| WO-2023225268-A1 | VANADYL SULFATE COMPOSITIONS AND METHODS OF USE THEREFOR FOR THE TREATMENT AND PREVENTION OF AGING-RELATED DISEASES AND CANCER | THE UNIVERSITY OF CHICAGO (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023215378-A1 | METHODS OF TREATING FIBROSIS | ATHIRA PHARMA, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023215376-A1 | METHODS OF TREATING NEUROPATHIES | ATHIRA PHARMA, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| EP-4236944-A1 | BICYCLIC COMPOUNDS AND USES THEREOF FOR THE TREATMENT OF DISEASES | Athira Pharma, Inc. (US) | 2023-09-06 | — | — | EP | disclosed |
| WO-2023114456-A1 | USES OF BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASES | ATHIRA PHARMA, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| EP-4178571-A1 | GAS41 INHIBITORS AND METHODS OF USE THEREOF | The Regents Of The University Of Michigan (US) | 2023-05-17 | — | — | EP | disclosed |
| WO-2023064218-A1 | TYRO3 INHIBITORS | Halia Therapeutics, Inc. (US) | 2023-04-20 | — | — | WO | disclosed |
| CN-113616656-B | Heterocyclic compounds for the treatment of PI 3K-gamma mediated disorders | 无限药品股份有限公司 | 2023-02-17 | — | — | CN | disclosed |
| WO-2022226182-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2022-10-27 | — | — | WO | disclosed |
| WO-2022204299-A1 | PYRIMIDINE DERIVATIVES USEFUL AS LRRK2 KINASE INHIBITORS | Halia Therapeutics, Inc. (US) | 2022-09-29 | — | — | WO | disclosed |
| WO-2022159835-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2022-07-28 | — | — | WO | disclosed |
| WO-2022094400-A1 | BICYCLIC COMPOUNDS AND USES THEREOF FOR THE TREATMENT OF DISEASES | ATHIRA PHARMA, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
| CN-114230571-A | Solid forms of isoquinolinones, methods of making, compositions containing, and methods of use thereof | 无限药品股份有限公司 | 2022-03-25 | — | — | CN | disclosed |